Qingsong Yu1, Fangrong Zhang2, Zhengde Du3, Yi Xiang2. 1. Department of Otolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China. 2. College of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology Wuhan, China. 3. Department of Otolaryngology, Nanshan People's Hospital Shenzhen, China.
Abstract
BACKGROUND: MiRNAs has been shown to be implicated in the pathogenesis of many human diseases including cancer. Dysregulation of miR-744 is common in a number of cancers, indicating miR-774 might be closely correlated with the tumorigenesis process. However, the role and clinical significance of miR-774 in nasopharyngeal carcinoma (NPC) is poorly known. Thus the aim of this study is to investigate whether there was any clinical value of serum miR-744 in detecting and predicting the prognosis of NPC. MATERIALS AND METHODS: Real-time PCR was used to examine the expression level of serum miR-744 in patients with NPC and the healthy volunteers. The changes in serum miR-744 expression level of NPC patients after receiving chemo-radiotherapy were also evaluated. The association between pre-treatment serum miR-744 expression level and NPC clinicopathological parameters was investigated. Finally we employed Kaplan-Meier method and Cox proportional hazards model to evaluate the clinical value of serum miR-744 in predicting the prognosis of NPC. RESULTS: Our study showed the expression level of serum miR-744 was significant higher in patients with NPC in comparison with healthy controls (P<0.01). The serum miR-744 expression level was down-regulated significantly in NPC patients after receiving chemo-radiotherapy (P<0.01). The Pre-treatment Serum miR-744 expression level was correlated with various important NPC clinicopathological parameters including N stage, clinical stage and grade. In addition, NPC patients with higher serum miR-744 expression had poorer 5 year overall survival rate and relapse-free survival rate. What was more, serum miR-744 was showed to be an independent factor for predicting the prognosis of NPC. CONCLUSION: Serum miR-744 was up-regulated in NPC patients. Higher expression level of serum miR-744 was closely correlated with was associated with poor prognosis in NPC and it might be employed as a potential biomarker for predicting the clinical outcome of NPC patients.
BACKGROUND: MiRNAs has been shown to be implicated in the pathogenesis of many human diseases including cancer. Dysregulation of miR-744 is common in a number of cancers, indicating miR-774 might be closely correlated with the tumorigenesis process. However, the role and clinical significance of miR-774 in nasopharyngeal carcinoma (NPC) is poorly known. Thus the aim of this study is to investigate whether there was any clinical value of serum miR-744 in detecting and predicting the prognosis of NPC. MATERIALS AND METHODS: Real-time PCR was used to examine the expression level of serum miR-744 in patients with NPC and the healthy volunteers. The changes in serum miR-744 expression level of NPCpatients after receiving chemo-radiotherapy were also evaluated. The association between pre-treatment serum miR-744 expression level and NPC clinicopathological parameters was investigated. Finally we employed Kaplan-Meier method and Cox proportional hazards model to evaluate the clinical value of serum miR-744 in predicting the prognosis of NPC. RESULTS: Our study showed the expression level of serum miR-744 was significant higher in patients with NPC in comparison with healthy controls (P<0.01). The serum miR-744 expression level was down-regulated significantly in NPCpatients after receiving chemo-radiotherapy (P<0.01). The Pre-treatment Serum miR-744 expression level was correlated with various important NPC clinicopathological parameters including N stage, clinical stage and grade. In addition, NPCpatients with higher serum miR-744 expression had poorer 5 year overall survival rate and relapse-free survival rate. What was more, serum miR-744 was showed to be an independent factor for predicting the prognosis of NPC. CONCLUSION: Serum miR-744 was up-regulated in NPCpatients. Higher expression level of serum miR-744 was closely correlated with was associated with poor prognosis in NPC and it might be employed as a potential biomarker for predicting the clinical outcome of NPCpatients.
Authors: Alpha Mu Nurul-Syakima; C Yoke-Kqueen; A R Sabariah; M S Shiran; A Singh; L Learn-Han Journal: Int J Mol Med Date: 2011-06-01 Impact factor: 4.101
Authors: J Lu; X Xu; X Liu; Y Peng; B Zhang; L Wang; H Luo; X Peng; G Li; W Tian; M He; X Li Journal: Br J Cancer Date: 2013-12-10 Impact factor: 7.640
Authors: Xiao Hong Peng; Hao Ran Huang; Juan Lu; Xiong Liu; Fei Peng Zhao; Bao Zhang; Shao Xiong Lin; Lu Wang; Huai Hong Chen; Xia Xu; Fan Wang; Xiang Ping Li Journal: Mol Cancer Date: 2014-08-07 Impact factor: 27.401